Neurocrine Biosciences ( (NBIX) ) has released its Q1 earnings. Here is a breakdown of the information Neurocrine Biosciences presented to its investors.
Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neuropsychiatric, neurological, and neuroendocrine disorders. The company offers FDA-approved treatments and has a robust pipeline of compounds in clinical development.
In the first quarter of 2025, Neurocrine Biosciences reported strong financial results with INGREZZA achieving net product sales of $545 million, marking an 8% growth compared to the previous year. The company also launched CRENESSITY, which generated $14.5 million in sales, and initiated significant clinical programs aimed at expanding its therapeutic offerings.
Key financial highlights include total revenues of $572.6 million, a 11% increase from the previous year. Despite increased R&D and SG&A expenses, driven by expanded clinical programs and product launches, the company maintained a strong balance sheet with $1.8 billion in cash and marketable securities. Neurocrine also initiated share repurchase programs, reflecting confidence in its financial stability.
The company continues to advance its clinical pipeline with Phase 3 programs for osavampator and NBI-568, targeting major depressive disorder and schizophrenia, respectively. These initiatives, alongside ongoing research, position Neurocrine for sustained growth in the neuroscience sector.
Looking ahead, Neurocrine Biosciences reaffirms its 2025 financial guidance, projecting INGREZZA net sales between $2.5 billion and $2.6 billion. The company remains committed to innovation and expanding its impact in treating complex neurological conditions.